SecurityDAL / Delta Air Lines, Inc.
InstitutionTide Point Capital Management, Lp
Shares817,409
Value $ 45,775,000
Related 247358AA2 / Delta Air Lines 4.75% 05/07/20

Tide Point Capital Management, Lp reports 29.58% decrease in ownership of DAL / Delta Air Lines, Inc.

February 14, 2018 - Tide Point Capital Management, Lp has filed a 13F-HR form disclosing ownership of 817,409 shares of Delta Air Lines, Inc. (NYSE:DAL) with total holdings valued at $45,775,000 USD as of December 31, 2017. Tide Point Capital Management, Lp had filed a previous 13F-HR on November 14, 2017 disclosing 1,160,713 shares of Delta Air Lines, Inc. at a value of $55,970,000 USD. This represents a change in shares of -29.58 percent and a change in value of -18.22 percent during the quarter.

Tide Point Capital Management, Lp has a history of taking positions in derivatives of the underlying security (DAL) in the form of stock options. The firm currently holds 0 call options valued at $0 USD .

Other investors with positions similar to Tide Point Capital Management, Lp include Manufacturers Life Insurance Company, The, Aberdeen Asset Management Plc/uk, AMF Pensionsforsakring AB, Federated Investors Inc /pa/, RidgeWorth Capital Management LLC, and Gotham Asset Management, LLC.

DELTA AIR LINES INC /DE/ has declared a standard industrial code (sic) of 4512 which is the "Air Transportation, Scheduled" industry. Tide Point Capital Management, Lp's top industries are "Metal Mining" (sic 10), "Fabricated Metal Products, Except Machinery And Transportation Equipment" (sic 34), and "Security And Commodity Brokers, Dealers, Exchanges, And Services" (sic 62).

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2017-12-31 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 52.11 817,409 -29.58 45,775 -18.22 -17,890 7,695 13.75
2017-09-30 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 1,160,713 55,970
2016-03-31 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 0 -100.00 0 -100.00
2015-12-31 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 47.78 700,000 -3.45 35,483 9.07 -1,195 4,147 12.75
2015-09-30 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 42.98 725,000 190.00 32,531 216.76 20,413 1,848 17.99
2015-06-30 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 43.02 250,000 -40.48 10,270 -45.61 -7,313 -1,300 -6.88
2015-03-31 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 47.07 420,000 -11.58 18,883 -19.18 -2,589 -1,893 -8.10
2014-12-31 13F-HR/A-1 DELTA AIR LINES INC DEL COM NEW 247361702 49.19 475,000 0.00 23,365 0.00 0 0 0.00
2014-12-31 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 475,000 23,365

Call Options

Effective
Date
Form Security Class CUSIP Opt Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2017-12-31 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 Call 0 -100.00 0 -100.00
2017-09-30 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 Call 527,500 25,436
2015-09-30 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 Call 0 -100.00 0 -100.00
2015-06-30 13F-HR DELTA AIR LINES INC DEL COM NEW 247361702 Call 400,000 16,432

Related SEC Filings

DAL / Delta Air Lines, Inc. / Berkshire Hathaway Inc - SC 13G/A (Passive Investment)

2018-02-15 sec.gov
SC 13G/A     SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)     DELTA AIR LINES, INC. (Name of Issuer)     COMMON STOCK (Title of Class of Securities) 247361702 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule

DAL / Delta Air Lines, Inc. / Berkshire Hathaway Inc - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
SC 13G/A     SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)     DELTA AIR LINES, INC. (Name of Issuer)     COMMON STOCK (Title of Class of Securities) 247361702 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule

DAL / Delta Air Lines, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-02-09 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) DELTA AIR LINES INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 247361702 -------------------------------------------------------- (CUSIP Number) January 31, 2018 -------------------------------------------------------- (Date of Event Whi

DAL / Delta Air Lines, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-02-09 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) DELTA AIR LINES INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 247361702 -------------------------------------------------------- (CUSIP Number) January 31, 2018 -------------------------------------------------------- (Date of Event Whi

DAL / Delta Air Lines, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
deltaairlinesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  Delta Air Lines Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  247361702     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Ru

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...



CUSIP: 247361702